EVA Pharma’s roots stretch back over a hundred years.

Our History

Our experienced leadership team keeps us on track.

Meet our Leaders

EVA Pharma’s success is based on its dynamic team, Our people are our power.

Life at EVA Pharma

GOLDEN, Colo., CAIRO, Egypt —&nbsp;&nbsp;26 June , 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling nee-dle-free injection technology, today announced that it has signed a Memorandum of Un-derstanding (MOU) agreement with the Egyptian Unified Procurement Authority (UPA) and EVA Pharma, one of the leading pharmaceutical companies driving healthcare in-novation and access across the Middle East and Africa, to explore the integration of needle-free delivery of inactivated polio vaccine into Egypt’s routine immunization pro-gram. The signing event took place in Cairo at the African Health ExCon healthcare conference on June 26. The agreement includes provisions for distribution, technology transfer, manufacturing, and new pharmaceutical product development, as well as col-laborating to increase needle-free access within Egypt and regionally.
&nbsp;
The UPA seeks to incorporate new technologies into its portfolio, aiming to expand the benefits of vaccination against certain infectious agents, improve pandemic prepared-ness, reduce total immunization costs, and improve foreign exchange rates. Tropis Nee-
dle-free adoption offers several strategic advantages for Egypt including substantial im-munization cost savings of 38% or more over six years1, reduced vaccine hesitancy2,3, increased coverage2, and the potential for medical technology localization.
&nbsp;
EVA Pharma is a leading pharmaceuticals and medical appliances manufacturing com-pany that has vast experience in manufacturing, registering, marketing, and promoting pharmaceutical products. “This collaboration can transform immunization by making it safer, more accessible, and less painful for children and caregivers,” said Nicolas Boege, Director of Global Commercial &amp; Corporate Development at EVA Pharma. “By introducing this technology, alongside localized technology transfer and manufacturing, EVA Pharma is committed to scaling innovation that strengthens public health systems. We are proud to collaborate with UPA and PharmaJet to localize needle-free delivery and accelerate its integration into Egypt’s immunization programs and beyond.”
&nbsp;
The adoption and introduction of Tropis with concurrent manufacturing technology transfer has the potential to advance UPA’s goal of becoming the leader of immuniza-tion excellence and a hub of needle-free product manufacturing for the Middle East and Northern Africa. The current initiative will enhance pandemic preparedness, reduce im-munization costs, and support Egypt’s Universal Health Insurance project. It also em-phasizes the critical importance of the first 1,000 days in a child’s life, building on the earlier efforts of the '1000 Golden Days' presidential initiative.
&nbsp;
“This collaboration with UPA and EVA Pharma has the potential to enable the children of Egypt to gain from the benefits of intradermal (ID) delivery with reduced pain and ad-ministration time. The UPA would benefit through cost savings and novel pharma prod-uct development and manufacturing opportunities with needle-free delivery, and we would be thrilled to expand PharmaJet’s commercial applications into Egypt and region-ally. It’s a win-win all around,” said Paul LaBarre, Vice President of Business Develop-ment for PharmaJet. “We look forward to contributing to early childhood development in this region by increasing the positive impact of needle-free immunization.”
Tropis ID has been widely used for inactivated polio vaccine delivery in campaigns and supplemental immunization activities. It has been rigorously evaluated in a routine im-munization setting in two recently published studies that showed greater than 94% ac-ceptability amongst healthcare workers and caregivers3, reduced administration time3, and greater than 50% reduction in immunization adverse events compared with intra-dermal delivery with a needle4.
&nbsp;
Refer to Instructions for Use to ensure safe injections and to review risks.
1 Data on file 2 Soonawala, D et al, Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults, Vac-cine, Volume 31, Issue 36, 12 August 2013, Pages 3688-3694 3 Mohan, D et al, Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria’s routine immunization pro-gram: An implementation hybrid trial , Vaccines,16 May 2025, 13(5), p.533 4 Resik, S et al, Tropis needle-free injector for fractional-dose IPV administration: A pilot study for integration into routine immuniza-tion services in Cuba. Vaccine, Volume 52 (2025), 126903
&nbsp;
&nbsp;
About PharmaJet
The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. Tropis® ID has CE Mark and WHO PQS certification for intradermal injections and is commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit https://www.pharmajet.com or contact PharmaJet here. Follow us on LinkedIn.
&nbsp;
About The Egyptian Unified Procurement Authority (UPA)
The Egyptian Unified Procurement Authority (UPA) is a government entity established to streamline and enhance the procurement of medical supplies, pharmaceuticals, and healthcare technologies in Egypt. Its primary goal is to improve the efficiency and effectiveness of the healthcare sector by ensuring timely and cost-effective acquisition of necessary resources. The UPA is a key component of Egypt's 2030 Vision for universal health coverage.
&nbsp;
About EVA Pharma
EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind capabilities to the Middle East and Africa including mRNA
research and development from AI prediction to biologic products. With a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies. Guided by a relentless drive to ensure sustainable access to pressing yet unmet disease areas, the company’s product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand. EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 70 countries worldwide. For more information, please visit: https://www.evapharma.com/en.

thumbnail_DSC_3989 copy (2) (1).jpg

DSC_3989 copy (2) (1).jpg

PharmaJet® Enters into MOU Agreement with Egyptian UPA and EVA Pharma to provide Needle-free Delivery for Routine Immunization in Egypt   Advancing Equitable Immunization Through Technology Transfer and Localized  Needle-Free Injection Manufacturing

PharmaJet Enters into MOU Agreement with Egyptian UPA and EVA Pharma to provide Needle-free Delivery for Routine Immunization in Egypt



PharmaJet® Enters into MOU Agreement with Egyptian UPA and EVA Pharma to provide Needle-free Delivery for Routine Immunization in Egypt Advancing Equitable Immunization Through Technology Transfer and Localized Needle-Free Injection Manufacturing

26 June, 2025

PharmaJet® Enters into MOU Agreement with Egyptian UPA and EVA Pharma to provide Needle-free Delivery for Routine Immunization in Egypt Advancing Equitable Immunization Through Technology Transfer and Localized Needle-Free Injection Manufacturing

26 June, 2025

Find out more about EVA Pharma

EVA Pharma’s roots stretch back over a hundred years.

Our experienced leadership team keeps us on track.

EVA Pharma’s success is based on its dynamic team, Our people are our power.